Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 125Neoplasm Metastasis 17Ovarian Neoplasms 12Endometrial Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Hereditary Sensory and Autonomic Neuropathies 5Colorectal Neoplasms 5Advanced Breast Cancer 5Squamous Cell Carcinoma of Head and Neck 4Stomach Neoplasms 3Recurrence 3Neoplasms by Site 3Head and Neck Neoplasms 3Carcinoma, Lobular 3Breast Diseases 3Breast Cancer Metastatic 3Uterine Neoplasms 2Small Cell Lung Carcinoma 2Multiple Endocrine Neoplasia Type 1 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumors 2Urologic Neoplasms 1Urogenital Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Fulvestrant × 1 year × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡